Skip to main navigation Skip to search Skip to main content

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

  • Marina Mesquida
  • , María Victoria Hernández
  • , Victor Llorenç
  • , Laura Pelegrín
  • , Gerard Espinosa
  • , Andrew D Dick
  • , Alfredo Adán

Research output: Contribution to journal › Article (Academic Journal) › peer-review

76 Citations (Scopus)

Abstract

Abstract Over the past decade, the off-label use of biologic agents such as TNF-α antagonists, including infliximab and adalimumab, has improved the treatment armamentarium for refractory immune-mediated uveitis, with particular success in Behçet disease-associated uveitis. Golimumab is a novel fully human anti-TNF-α monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with very promising results. Herein, the authors present the use of GLM in a case of Behçet uveitis refractory to other TNF-α blockers. There are only two reports in the literature about the use of GLM in uveitis, describing four patients with JIA-associated uveitis and a case of idiopathic retinal vasculitis. To the authors' knowledge, this is the first report about the use of GLM in Behçet uveitis.
Original languageEnglish
JournalOcular Immunology and Inflammation
DOIs
Publication statusPublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Behçet Disease-associated Uveitis Successfully Treated with Golimumab'. Together they form a unique fingerprint.

Cite this